Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Anavex Life Sciences Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.535 I will be your host for today's call. At this time, all participants are in a listen-only 00:00:04.535 -- 00:00:08.779 mode. Later, we will conduct a question-and-answer session, and during this session, 00:00:08.779 -- 00:00:12.823 if you would like to ask a question, please use the Q&A box or raise your hand. 00:00:12.823 -- 00:00:16.166 Please note that this conference is being recorded, and the call will be available for 00:00:16.166 -- 00:00:20.488 replay on Anavex's website at www.anavex.com. 00:00:21.491 -- 00:00:26.055 With us today is Dr. Christopher Misling, President and Chief Executive Officer, and 00:00:26.055 -- 00:00:29.697 Sandra Burnish, Principal Financial Officer. 00:00:29.697 -- 00:00:32.961 Before we begin, please note that during this conference call, the company will make 00:00:32.961 -- 00:00:36.105 some projections and forward-looking statements. 00:00:36.105 -- 00:00:40.650 These statements are only predictions based on current information and expectations and 00:00:40.650 -- 00:00:43.434 involve a number of risks and uncertainties. 00:00:43.434 -- 00:00:48.980 We encourage you to review the company's filings with the SEC that include, without limitation, 00:00:48.980 -- 00:00:54.147 the company's forms 10-K and 10-Q, which identify the specific factors that may cause 00:00:54.147 -- 00:00:58.071 actual results or events to differ materially from those described in these forward-looking 00:00:58.071 -- 00:00:59.617 statements. 00:00:59.617 -- 00:01:04.707 These factors may include without limitation risks inherent in the development and or 00:01:04.707 -- 00:01:09.857 commercialization of potential products, uncertainty in the results of clinical trials 00:01:09.857 -- 00:01:14.907 or regulatory approvals,...